---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-181344"
form_type: "8-K"
ticker: "ALDX"
cik: "0001341235"
company_name: "Aldeyra Therapeutics, Inc."
filed_at: "2023-07-03T23:59:59+00:00"
generated_at: "2026-06-13T13:08:58.363334+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Aldeyra shareholders elect Brady and Joyce as Class III directors, approve 2023 equity plan

## Summary
- Director Todd C. Brady reelected with 21,007,679 votes for, 7,405,955 withheld.
- Director Martin J. Joyce elected with 16,126,225 votes for, 12,287,409 withheld.
- Ratification of BDO USA as auditor approved: 43,474,045 for, 25,820 against.
- Advisory vote on executive compensation approved: 27,710,251 for, 57,323 abstain.
- 2023 Equity Incentive Plan approved: 27,066,030 for, 1,293,014 against.

## SEC filing metadata
- accession: 0001193125-23-181344
- form_type: 8-K
- ticker: ALDX
- cik: 0001341235
- company_name: Aldeyra Therapeutics, Inc.
- filed_at: 2023-07-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1341235/000119312523181344/0001193125-23-181344-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1341235/000119312523181344/d431816d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-181344
- JSON: https://secwatch.observer/filing/0001193125-23-181344.json
- Plain text: https://secwatch.observer/filing/0001193125-23-181344.txt

## Key facts
- Shareholder Votes
  Aldeyra Therapeutics, Inc. shareholders approved Election of two directors to serve as Class III directors until the Company’s 2026 annual meeting at the 2023-06-30 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-30
  source text: Proposal 1: Election of Directors. The Company’s stockholders elected the following directors to serve as Class III directors until the 2026 annual meeting of stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal. The votes regarding the election of the directors were as follows: Director Votes For Votes Withheld Broker Non-Votes Todd C. Brady, M.D., Ph.D. 21,007,679 7,405,955 15,106,765 Martin J. Joyce, M.B.A. 16,126,225 12,287,409 15,106,765
  evidence_url: https://www.sec.gov/Archives/edgar/data/1341235/000119312523181344/0001193125-23-181344-index.htm
- Shareholder Votes
  Aldeyra Therapeutics, Inc. shareholders approved Ratification of the appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-30 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-30
  source text: Proposal 2: Ratification of Appointment of BDO USA, LLP. The Company’s stockholders ratified the appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The votes regarding this proposal were as follows: Votes For Votes Against Votes Abstaining 43,474,045 25,820 20,534
  evidence_url: https://www.sec.gov/Archives/edgar/data/1341235/000119312523181344/0001193125-23-181344-index.htm
- Shareholder Votes
  Aldeyra Therapeutics, Inc. shareholders approved Approval of the adoption of the Aldeyra Therapeutics, Inc. 2023 Equity Incentive Plan at the 2023-06-30 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2023-06-30
  source text: Proposal 4: Approval of the Adoption of the Aldeyra Therapeutics, Inc. 2023 Equity Incentive Plan. The Company’s stockholders approved the adoption of the Aldeyra Therapeutics, Inc. 2023 Equity Incentive Plan as described in the Proxy Statement. The votes regarding this proposal were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 27,066,030 1,293,014 54,590 15,106,765
  evidence_url: https://www.sec.gov/Archives/edgar/data/1341235/000119312523181344/0001193125-23-181344-index.htm
- Shareholder Votes
  Aldeyra Therapeutics, Inc. shareholders approved Non-binding, advisory vote on the compensation of the Company’s named executive officers at the 2023-06-30 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-06-30
  source text: Proposal 3: Advisory Vote on Executive Compensation. The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers as described in the Proxy Statement. The votes regarding this proposal were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 27,710,251 646,060 57,323 15,106,765
  evidence_url: https://www.sec.gov/Archives/edgar/data/1341235/000119312523181344/0001193125-23-181344-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.